CLEARSIDE BIOMEDICAL INC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 30
- Market Cap
- $75.4M
- Website
- http://www.clearsidebio.com
Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2021-05-28
- Lead Sponsor
- Clearside Biomedical, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT02595398
- Locations
- 🇺🇸
Emory Eye Center Emory University, Atlanta, Georgia, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸Elman Retina Group, PA, Baltimore, Maryland, United States
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-11-27
- Last Posted Date
- 2021-02-08
- Lead Sponsor
- Clearside Biomedical, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT02303184
Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-10-02
- Last Posted Date
- 2021-02-08
- Lead Sponsor
- Clearside Biomedical, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT02255032
Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-02-12
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Clearside Biomedical, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT01789320
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
© Copyright 2024. All Rights Reserved by MedPath